Neoadjuvant Chemoradiation Plus Immunotherapy Boosts Responses in Esophageal Cancer

(MedPage Today) -- SAN FRANCISCO -- Neoadjuvant chemoradiotherapy with or without the investigational PD-1 inhibitor sintilimab significantly increased pathological complete response (pCR) rates compared with neoadjuvant chemotherapy plus sintilimab...